C. Anne Higley
Wilmington University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by C. Anne Higley.
Bioorganic & Medicinal Chemistry Letters | 1998
John V. Duncia; Joseph B. Santella; C. Anne Higley; William John Pitts; John Wityak; William E. Frietze; F.Wayne Rankin; Jung-Hui Sun; Richard A. Earl; A.Christine Tabaka; Christopher A. Teleha; Karl F. Blom; Margaret F. Favata; Elizabeth J. Manos; Andrea J. Daulerio; Deborah A. Stradley; Kurumi Y. Horiuchi; Robert A. Copeland; Peggy Scherle; James M. Trzaskos; Ronald L. Magolda; George L. Trainor; Ruth R. Wexler; Frank W. Hobbs; Richard E. Olson
In search of antiinflammatory drugs with a new mechanism of action, U0126 was found to functionally antagonize AP-1 transcriptional activity via noncompetitive inhibition of the dual specificity kinase MEK with an IC50 of 0.07 microM for MEK 1 and 0.06 microM for MEK 2. U0126 can undergo isomerization and cyclization reactions to form a variety of products, both chemically and in vivo, all of which exhibit less affinity for MEK and lower inhibition of AP-1 activity than parent, U0126.
Bioorganic & Medicinal Chemistry Letters | 1998
John V. Duncia; Joseph B. Santella; C. Anne Higley; Mary K. VanAtten; Patricia C. Weber; Richard S. Alexander; Charles A. Kettner; James Russell Pruitt; Anne Y. Liauw; Mimi L. Quan; Robert M. Knabb; Ruth R. Wexler
Substituted pyrazoles, 1,2,4-triazoles, and tetrazoles are good surrogates for cis-amide bonds in a series of boronate ester thrombin inhibitors.
Bioorganic & Medicinal Chemistry Letters | 1995
Richard Gerald Wilde; Jeffrey T. Billheimer; Sandra J. Germain; Peter J. Gillies; C. Anne Higley; Hollis S. Kezar; Thomas P. Maduskuie; Edward S. Shimshick; Ruth R. Wexler
Abstract A series of compounds bearing heterocyclic substituents were prepared, and evaluated for inhibition of the ACAT enzyme. The heterocyclic groups were compared in terms of in vitro potency against their diarylimidazole analogues. Data for the purposes of QSAR were also collected. Our goal is a systemic ACAT inhibitor, which would be a potential antihypercholesterolemic and antiatherosclerotic agent.
Journal of Medicinal Chemistry | 1997
Chu-Biao Xue; John Wityak; Thais M. Sielecki; Donald J. P. Pinto; Douglas G. Batt; Gary A. Cain; Michael Sworin; A. L. Rockwell; John Roderick; Shuaige Wang; Michael J. Orwat; William E. Frietze; Lori L. Bostrom; Jie Liu; C. Anne Higley; F.Wayne Rankin; A. Ewa Tobin; George Emmett; George K. Lalka; Jean Y. Sze; Susan V. Di Meo; Shaker A. Mousa; Martin J. Thoolen; Adrienne L. Racanelli; Elizabeth A. Hausner; Thomas M. Reilly; William F. DeGrado; and Ruth R. Wexler; Richard E. Olson
Journal of Medicinal Chemistry | 2002
Eddy W. Yue; C. Anne Higley; Susan V. Dimeo; David John Carini; David A. Nugiel; Carrie Benware; Pamela A. Benfield; Catherine R. Burton; Sarah Cox; Robert H. Grafstrom; Lisa Sisk; John F. Boylan; Jodi K. Muckelbauer; Angela Smallwood; Haiying Chen; Chong-Hwan Chang; Steven P. Seitz; George L. Trainor
Archive | 2001
Charles F. Albright; Andrew P. Combs; Robert A. Copeland; Susan V. Dimeo; Radine L Dowling; Nilsa R. Graciani; Wei Han; C. Anne Higley; Pearl S. Huang; Eddy W. Yue
Archive | 1993
Richard Gerald Wilde; C. Anne Higley; Jeffrey T. Billheimer; Ruth R. Wexler
Archive | 1991
Jeffrey T. Billheimer; Peter J. Gillies; C. Anne Higley; Thomas P. Maduskuie; Ruth R. Wexler
Archive | 1989
Jeffrey T. Billheimer; Peter J. Gillies; Ruth R. Wexler; C. Anne Higley; Thomas P. Maduskuie
Archive | 1989
Jeffrey T. Billheimer; Peter J. Gillies; Ruth R. Wexler; C. Anne Higley; Thomas P. Maduskuie